Coya Therapeutics, Inc. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Coya Therapeutics reported Q2 2026 net loss of $6.6M (vs. $6.1M YoY), with cash and equivalents of $43.2M as of June 30, 2026. The company advanced COYA 302 in ALS Phase 2 (ALSTARS trial enrollment proceeding as planned, topline Q1 2027), received FDA Fast Track Designation for ALS, and plans to initiate Phase 2 in frontotemporal dementia in coming months. R&D expenses increased $1.3M to $5.0M (primarily COYA 302 clinical trial costs); G&A decreased $0.6M to $2.3M. Cash runway extends past Phase 2 topline and into H2 2027. Share count increased from 20.9M (Dec 2025) to 23.5M (June 2026) following $10.95M equity financing.
Why this rating
Clinical progress (FDA Fast Track, enrollment on schedule) is positive; modest operating cash burn ($13.6M H1 2026) and adequate runway ($43.2M, ~48% of market cap) are manageable. Near-term catalysts (enrollment completion, FTD trial initiation, biomarker data) are normal development milestones. No material deal, financing distress, or trajectory shift; routine biotech progression.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.